Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cromolyn + TQB2102 + penpulimab
- Development stage
- Unknown
- Lead developer
- Fudan University
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intranasal, Intravenous
01
Overview
This investigational triple-combination therapy is being evaluated for the treatment of immune-refractory triple-negative breast cancer (TNBC). It comprises cromolyn sodium, a mast cell stabilizer; TQB2102, a HER2-directed antibody-drug conjugate (ADC); and penpulimab (also referred to as panpulimab), a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. The rationale for this combination, studied in the Phase II RECLAIM trial by Fudan University, is to overcome resistance to immunotherapy. Cromolyn is hypothesized to mobilize mast cell-mediated T-cell immunity, potentially sensitizing the tumor microenvironment to PD-1 blockade, while TQB2102 provides targeted delivery of a cytotoxic payload to HER2-expressing cells within the TNBC population.
- Brand names
- Anniko
- Other names
- panpulimabcromolyn sodiumpenpulimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on cromolyn + TQB2102 + penpulimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cromolyn + TQB2102 + penpulimab.